About: admin

SHENZHEN, CHINA, Mar 5, 2026 – (ACN Newswire) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that self-developed innovative drug INHBE-targeting small nucleic acid drug CMS-D008 injection (“CMS-D008”) received the Drug Clinical Trial Approval Notice issued by National Medical Products Administration (“NMPA”) on 4 March 2026. The NMPA has approved the conduct of clinical trials of CMS-D008 injection for overweight or obese individuals. About CMS-D008 CMS-D008 is a novel siRNA therapy administered by subcutaneous injection. CMS-D008 targets and reduces the hepatic expression of the inhibin subunit beta E (INHBE) gene and lowers the level of Activin E protein encoded by INHBE, which blocks Activin E-ALK7 signaling and reduces fat accumulation effectively. Preclinical studies suggested that CMS-D008 efficiently and sustainably suppressed INHBE expression. In the diet-induced obesity model, CMS-D008 enhanced weight loss by reducing fat mass while retaining lean mass with a good safety profile. It demonstrates potentially better prospects for high-quality, long-term weight loss that boosts fat-specific loss while preserving muscle mass. In the future, it may be developed for the treatment of overweight/obesity, abdominal obesity, and related metabolic diseases. Fat Loss, muscle preserved: a potentially better therapeutic option for overweight/obesity Overweight or obesity is a chronic, progressive, relapsing disease characterized by excessive accumulation or abnormal distribution or function of body fat[1]. World Obesity Atlas 2025 Report projected that the global proportion of overweight and obese adults will rise to 50%, with nearly 3 billion adults impacted by high body mass index (BMI), and the population of adults who are overweight or obese in China is projected to reach 515 million by 2030[2]. Existing GLP-1RAs have been proven to be effective for the treatment of overweight and obesity. The main actions of GLP-1RAs are to suppress appetite by acting on the central nervous system and to delay gastric emptying[3]. INHBE’s novel mechanism of action differs from GLP-1RAs. INHBE is identified through genome-wide association studies. Populations with loss of function in INHBE are associated with favorable fat distribution and beneficial metabolic characteristics[4]. Targeted inhibition of INHBE might be more conducive for long-term weight management at the genetic level with precisely lower visceral fat and favorable metabolic profiles. CMS-D008 teams up with CMS-D005: highly effective weight loss plus long-term maintenance, building a more comprehensive weight-loss solution CMS-D008 will synergize with CMS-D005, a self-developed innovative drug currently in clinical development. CMS-D008 reduces fat without sacrificing muscle mass by precisely inhibiting INHBE gene expression; while CMS-D005, as a GLP-1R/GCGR dual agonist, can effectively reduce liver fat while losing weight. The synergy between these two drugs will achieve highly effective weight loss benefits and long-term maintenance of results, jointly enhancing the Group’s R&D capabilities and product competitiveness in the field of obesity/metabolic treatment. Furthermore, leveraging the Group’s mature network resources in the field of cardiovascular and metabolic diseases, the drug’s R&D and commercialization process will be accelerated, providing patients with more comprehensive and innovative treatment options. The Group is actively preparing to initiate relevant clinical trials and strives to launch the Product as soon as possible. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference: 1. Chinese Society of Endocrinology. Guideline for chronic weight management and clinical practice of anti-obesity medications(2024 version). Chinese Journal of Endocrinology and Metabolism. 2024,40(7):545-564. 2. World Obesity Federation. World Obesity Atlas 2025. London: World Obesity Federation, 2025. https://data.worldobesity.org/publications/?cat=23 3. Zhikai Zheng, Yao Zong, Yiyang Ma, Yucheng Tian, Yidan Pang, Changqing Zhang, Junjie Gao. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Sig Transduct Target Ther 9, 234 (2024). doi: 10.1038/s41392-024-01931-z 4. Parsa Akbari, Olukayode A Sosina, Jonas Bovijn, et al. Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes. Nat Commun.2022 Aug 23;13(1):4844. doi: 10.1038/s41467-022-32398-7. CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

Singapore – March 05, 2026 – (SeaPRwire) – Core Concepts Physio, one of Singapore’s leading physiotherapy providers, has announced an expanded collaborative programme with podiatry service provider, Podiatry Quest, to offer enhanced, multidisciplinary assessments for patients experiencing plantar fasciitis and stubborn heel pain. Plantar fasciitis remains one of the most common and persistent causes of heel pain among adults, especially those with active lifestyles or occupations involving long hours on their feet. Often treatment seeks to address only one aspect of the condition rather than the full movement chain, which leads to recurring pain as other aspects remain unresolved. To bridge this gap, the two clinics have formalised a joint assessment pathway that evaluates plantar fasciitis from both the top-down (physiotherapy) and the bottom-up (podiatry) so as to ensure that no contributing factor is overlooked. A Smarter, More Complete Way to Diagnose Heel Pain Physiotherapy and podiatry traditionally manage different elements of plantar fasciitis. Physiotherapists focus on mobility, strength, gait and load tolerance, while podiatrists address foot posture, footwear, ground forces and orthotic support. The new integrated pathway combines both perspectives into a single, coordinated evaluation which results in: More accurate, holistic diagnoses Fully optimised treatment strategies Fewer flare-ups and recurrences Clearer, consistent guidance for patients Faster and more sustainable outcomes “Many patients struggle because plantar fasciitis isn’t caused by just one issue,” said Mr Chng Chye Tuan, Senior Principal Physiotherapist at Core Concepts Physiotherapy. “It’s a movement chain problem involving the foot, calf, ankle mobility, daily load and footwear. When physiotherapists and podiatrists work together, we address every contributing factor — not just the symptoms.” A Case Study Demonstrating Collaborative Success In a recent case, a 42-year-old recreational runner sought help after six months of persistent heel pain. Physiotherapy improved his morning pain and running tolerance, but he continued to experience flare-ups following long work shifts. A podiatry assessment revealed prolonged pronation, footwear-related loading issues and inadequate shock absorption. With customised orthoses and tailored footwear recommendations, the patient’s daily load decreased significantly — allowing physiotherapy progress to continue without setbacks. Within 10 weeks of coordinated care, he achieved pain-free mornings, comfortable workdays and full return to running. “This case reflects what we see frequently,” said Mr Yeo Boon Kiak, Principal Podiatrist at Podiatry Quest. “Physiotherapy builds tissue capacity, strength and movement control. Podiatry reduces unnecessary strain and optimises how forces enter the foot. When combined, this creates the ideal environment for long-lasting recovery.” Making Multidisciplinary Care Accessible Nationwide Through this collaboration, patients with plantar fasciitis now benefit from: Joint physiotherapy–podiatry assessments Aligned clinical decision-making Consistent communication across providers A thorough evaluation of both the cause and consequence of heel pain A fully optimised recovery pathway “Our multidisciplinary team brings together the best of both professions,” said Mr Chng Chye Tuan. “Whether someone is a runner, a frequent traveller or stands long hours at work, this collaboration ensures their care is comprehensive, precise and built around their real-life demands.” About Core Concepts Physiotherapy Core Concepts Physio is one of Singapore’s largest private physiotherapy groups, offering evidence-based musculoskeletal and sports physiotherapy across multiple clinic locations. Their multidisciplinary approach allows clients to benefit from integrated care, ensuring complete and effective recovery. Know more please contact marketing@coreconcepts.com.sg or call +65 62263632 or visit our office at 6 Raffles Quay, #11-01, Singapore 048580. About Podiatry Quest Podiatry Quest specialises in diagnosing and treating foot, ankle and lower limb conditions. Led by experienced podiatrists, the clinic offers services such as customised orthoses, biomechanical assessments, gait analysis and comprehensive podiatric care. Contact Details Organization: Core Concepts Pte Ltd Contact: Clemence Lim Email: marketing@coreconcepts.com.sg Website: https://www.coreconceptsphysio.sg

Base58 Labs Advances Integration of Proprietary BHLE Infrastructure LONDON, United Kingdom – March 04, 2026 – (SeaPRwire) – BASIS has announced a significant acceleration in platform development following its recent $35 million Pre-Series A capital raise. The funding enables parent company Base58 Labs to advance the commercial integration of its proprietary Base58 Hyper-Latency Engine (BHLE) into the BASIS staking infrastructure. BHLE, developed over multiple years within institutional high-frequency trading (HFT) research environments, is now transitioning from research phase into structured platform deployment. The engine is designed to enhance execution efficiency, reduce latency-related inefficiencies, and optimise liquidity management across fragmented digital asset markets. Industry observers note that the integration of institutional-grade execution frameworks into a staking infrastructure model represents a strategic evolution within the broader digital asset ecosystem. While detailed technical specifications remain confidential, Base58 Labs confirmed that BHLE will serve as a core execution layer within the BASIS architecture. In parallel with the technical acceleration, Base58 Labs has initiated a large-scale recruitment programme across Europe and the United Kingdom. The company is onboarding quantitative engineers, blockchain systems architects, and regulatory compliance specialists, all of whom will focus exclusively on BASIS platform development and infrastructure scaling. “Our objective is to combine years of proprietary research with expanded operational capacity,” a company spokesperson stated. “The recent capital raise enables us to consolidate technical, intellectual, and human resources around a single mission: delivering a high-performance staking infrastructure aligned with institutional standards.” BASIS is also being developed with regulatory alignment in mind, including adherence to emerging European frameworks such as MiCA (Markets in Crypto-Assets). The platform aims to provide a structurally robust environment for both institutional and retail participants. With liquidity reserves strengthened and integration milestones progressing, BASIS remains on track for an official launch in the second half of 2026. About Base58 Labs Base58 Labs is a London-based digital infrastructure company specialising in high-performance execution technologies and blockchain optimisation systems. Learn more: https://base58labs.com/ Media Contact Base58 Labs PR Team Email: info@base58labs.com BASIS Official Website: https://basis.pro/ Base58 Labs Official Website: https://base58labs.com/

Tashkent, Uzbekistan – March 04, 2026 – (SeaPRwire) – FinHarbor, a modular financial infrastructure provider, has completed the core phase of a hybrid neobank platform for Asterium – a licensed fintech project in Uzbekistan that combines traditional banking with digital asset services under a single regulated framework. Why Uzbekistan – Uzbekistan is actively building a regulated environment for digital assets. The country has introduced a national distributed ledger system (Mirasmanda) and a state-backed digital asset (HUMO), supervised by the National Agency for Perspective Projects (NAPP). For infrastructure providers, this creates a rare opportunity: a market where crypto and banking can coexist within a clear legal perimeter. Asterium’s project is designed to operate fully within this framework. What Was Deployed – FinHarbor adapted its microservices-based platform to the requirements of the Uzbek market and Asterium’s business model. The core deployment covers three key layers: Banking infrastructure – management of fiat accounts, issuance of physical and virtual bank cards (VISA, MasterCard, HUMO), and integration with local processing systems. Digital asset infrastructure – crypto account management, integration with Bitcoin, Ethereum, and Tron networks, as well as native connection to Uzbekistan’s Mirasmanda ledger for HUMO asset support. Compliance and exchange – a unified KYC/KYB/AML/KYT module aligned with local and international standards, integration with global AML/KYT providers, and multiple exchange models including fiat-to-crypto, crypto-to-fiat, and crypto-to-crypto conversions with card-based ramp-in and ramp-off. The result is a single platform where users can hold bank accounts and crypto wallets, exchange assets, and use cards – all within a regulated environment. How the Partnership Works – FinHarbor operates as Asterium’s strategic technology partner, not just a software vendor. A dedicated implementation team supports the platform on an ongoing basis, managing feature rollouts and infrastructure expansion. “This project required deep architectural customization – from integrating with a national blockchain system to building compliance workflows that satisfy both local regulators and international standards,” said Ilya Podoynitsyn, CEO of FinHarbor. “The core phase is complete, and we are already scaling the platform with new products and business use cases.”   What’s Next – With the core infrastructure live, FinHarbor and Asterium are moving into the next stage: launching consumer-facing products and expanding the platform’s functionality to support additional business lines built on the deployed stack. About FinHarbor FinHarbor provides modular technology infrastructure for launching compliant financial products – from wallets and neobanks to crypto ramps and OTC desks. The platform supports fiat, crypto, and hybrid business models, with ISO/PCI DSS-certified architecture and deployment options across Europe, MENA, and CIS markets. Social Links LinkedIn: https://www.linkedin.com/company/finharbor/ Blog: https://www.finharbor.com/blog Media contact Brand: FinHarbor Contact: Media team Email: press@finharbor.com Website:  https://www.finharbor.com/

Hong Kong – March 02, 2026 – (SeaPRwire) – At the India AI Impact Summit 2026, AI Safety Asia (AISA) convened two important conversations on the future of AI governance. The first examined how governments should respond when AI-related crises unfold across borders at machine speed. The second marking the launch of the International AI Safety Report 2026. Taken together, these sessions showed a change in the debate; moving past whether AI should be governed to a focus on how. Who verifies claims made by powerful systems? Who coordinates when an incident crosses jurisdictions in seconds? Who is responsible when an autonomous system acts, and no single ministry appears in charge? As AI systems become more agentic and embedded deeper into critical infrastructure, they are forcing diplomatic and regulatory institutions to respond in real time. The pressure on diplomatic and regulatory institutions is no longer just a theory, it is operational. Governing AI in a Fragmented World On 17 February at Bharat Mandapam, AISA co-hosted the session “AI Crisis Diplomacy: Governing AI in a Fragmented World” in partnership with the Center for Human-Compatible AI (CHAI) and the International Association for Safe and Ethical Artificial Intelligence (IASEAI). The session brought together senior experts in the space; Professor Stuart Russell, Audrey Tang, Dr. Yuko Harayama, Wan Sie Lee, and Azizjon Azimi, moderated by AISA’s Chief Strategy Officer, Adjunct Professor Alejandro Reyes. Rather than rehearse abstract debates about regulation, the discussion focused on plausible crisis scenarios: a cross-border deepfake incident that destabilises diplomatic relations before verification catches up; an AI-enabled cyberattack cascading across jurisdictions; an autonomous infrastructure system operating in one country, hosted in another, and affecting a third. The problem is not only detection. It is coordination under uncertainty. The familiar argument that AI evolves too quickly to regulate was put under scrutiny. The pace of innovation does not make governance obsolete. Aviation, nuclear energy, and pharmaceuticals are governed by setting acceptable risk thresholds and requiring evidence that systems meet them. AI should be treated no differently. Governments need to insist on demonstrable safety and credible liability frameworks, rather than accepting disclaimers and opaque risk claims. Governments already know how to cooperate during crises. Pandemic response and cybersecurity have shown that cross-border coordination is possible. The gap in AI governance is not diplomatic architecture in principle, but operational channels between those responsible for technical evaluation. Joint testing efforts are not only about measuring model performance. They build trust, and trust is what allows regulators to pick up the phone, compare signals, and verify before escalation spirals. AI does not create entirely new categories of crisis, but amplifies existing ones. What changes is speed and scale. Human institutions deliberate; AI systems act, and bridging that gap requires new protocols, shared verification standards, and regular engagement long before a crisis forces coordination under pressure. Governance capacity matters, and durable infrastructure outperforms isolated interventions. Crisis diplomacy cannot be improvised, it must be built through trusted networks, regionally grounded expertise, and repeat engagement. The Evidence Dilemma and the 2026 International AI Safety Report On 18 February, AISA co-hosted the International AI Safety Report 2026 Launch Reception at the High Commission of Canada in India, in partnership with the High Commission, the UK AI Security Institute, and Mila – Quebec Artificial Intelligence Institute. The event featured Professor Yoshua Bengio, Chair of the Report and Founder and Scientific Advisor of Mila, supported by co-leads Carina Prunkl and Stephen Clare. The report provides an independent scientific assessment of frontier general-purpose AI capabilities and risks; focusing on emerging risks, including malicious use, autonomous malfunctions, and systemic disruption, and confronts the evidence dilemma. Policymakers must act under conditions of uncertainty, yet waiting for perfect data runs the risk of leaving societies exposed. The Report documents rapid advances in reasoning systems and AI agents, as well as continued reliability challenges, risks in cyber and bio domains, and growing systemic concern; underscoring that risk management cannot rely on a single safeguard. Technical measures, institutional oversight, and societal resilience must be layered. The choice is not between innovation and safety, it is between unmanaged acceleration and accountable progress. Evidence standards, robust evaluations, and credible thresholds are essential if public trust is to keep pace with technical capability. For countries across Asia and the broader Global South, the issue is how to shape governance frameworks that reflect local institutional realities while contributing to global norms. AISA’s mission is to ensure that regional expertise informs both national decisions and international debates. From Conversation to Capacity AI governance is not a single regulatory instrument. It is an evolving institutional practice. The next phase will be defined less by declarations and more by whether governments can verify claims, share information at speed, and operationalise coordination before crises escalate. Asia is not waiting for governance models to arrive from elsewhere. Across the region, policymakers, regulators, and technical experts are building their own capacity to govern frontier technologies responsibly, shaped by local realities and regional priorities. The next AI-driven crisis will not unfold on a diplomatic timetable; it will move at machine speed. Whether diplomacy and safety can keep up will depend on the institutions, relationships, and verification channels being built now, not after the fact. About AI Safety Asia AI Safety Asia (AISA) believes progress in AI must begin with people. Since 2024, AISA has engaged more than 2,000 AI governance professionals across 16 Asian countries. Its work centres on building durable governance infrastructure: research that is regionally grounded, structured peer learning, and implementation-oriented engagement. AISA helps build capacity, bringing together policymakers, experts, and civil society to strengthen the knowledge, networks, and trust required to govern frontier technologies responsibly, grounded in regional realities. The institutions and relationships built today will determine whether diplomacy and safety can keep up. Social Link LinkedIn: https://www.linkedin.com/company/ai-safety-asia/ Media Contact Brand: AI Safety Asia Contact: Media team Email: contact@aisafety.asia Website: https://www.aisafety.asia

SHENZHEN, Feb 24, 2026 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received the acceptance from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of mild to moderate atopic dermatitis on 24 February 2026. The Product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NDA has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”, which is expected to accelerate the Product’s review process for marketing approval in the AD indication. Impressive phase III trial data in AD Its Priority Review is expected to accelerate its NDA approval Ruxolitinib phosphate cream was approved for marketing by the NMPA in January 2026, becoming the first and only targeted drug approved in China for the treatment of vitiligo. The acceptance of this NDA for the additional indication of AD marks a key milestone in the Product’s expansion into multiple therapeutic areas. Ruxolitinib phosphate cream has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical trial in China for mild to moderate AD. Robust Efficacy: The Product successfully met its primary endpoint, demonstrating that a significantly higher proportion of subjects treated with ruxolitinib phosphate cream achieved IGA (Investigator’s Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P < 0.001). For the key secondary endpoint, the proportion of subjects achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with ruxolitinib phosphate cream was also significantly higher than that of the placebo group, at week 8 (78.0% vs 15.4%, P < 0.001). Favorable Safety Profile: The severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, ruxolitinib phosphate cream was safe and well-tolerated. Furthermore, the NDA has been approved for inclusion in the Priority Review List. According to relevant NMPA regulations, the review timeline for marketing applications subject to Priority Review and Approval Procedure is substantially shortened—from the standard 200 days to 130 days. This significant reduction in the review timeline is expected to accelerate the marketing process of ruxolitinib phosphate cream for the AD indication, benefiting a wide range of patients at an earlier date. Building an integrated AD solution, strengthening Dermavon’s leadership in dermatology AD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there were over 54 million AD patients in China as of 2024. Based on SCORAD scores, mild to moderate AD accounts for 98% of these cases, representing over 52.5 million patients[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed. Dermavon has developed a comprehensive “treatment + care” integrated solution for AD. In addition to the topical formulation ruxolitinib phosphate cream for mild-to-moderate AD, the portfolio also includes the injectable biological agent Comekibart Injection (MG-K10) for moderate-to-severe AD, the oral small molecule targeted drug CMS-D001 for moderate-to-severe AD, and the Heling Soothing Product Series for daily repair, to meet the management needs of AD patients from treatment to daily care. Simultaneously, the acceptance of the NDA for the AD indication will strengthen Dermavon’s strategic layout in the field of skin treatments and create synergies with its commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon’s market competitiveness and brand influence in the field of skin health. More Information About Ruxolitinib Phosphate Cream Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte. In China, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. In the U.S., ruxolitinib phosphate cream is the first topical JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of non-segmental vitiligo in patients aged 12 years and older, and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable[2]. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3]. The Group, through its subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary). Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference:1. China Insights Consultancy’s industrial report2. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib3. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/

JIAXING, China – February 13, 2026 – On the eve of the 2026 Spring Festival, the “Relax Jiaxing” international promotional campaign, organized by the Jiaxing Municipal Bureau of Culture, Radio, Television, and Tourism in partnership with Putike International Travel Service,was successfully launched. The initiative invited celebrated Malaysian travel content creators @Janice&Jaguar on a curated three-day journey through Jiaxing, designed to capture the authentic flavors of the Chinese New Year and the timeless allure of the Jiangnan region. Documenting their experiences and sharing them with global audiences via Instagram, YouTube, and other international social media platforms, the influencers spotlighted Jiaxing’s vibrant Spring Festival traditions and distinctive Jiangnan character, extending an invitation to overseas travelers to “come back to Jiaxing and experience the festivities.” Where the Festive Spirit Reigns: Jiaxing Debuts Its Captivating “Chinese New Year Look” The meticulously curated itinerary, built around the theme of “New Year flavor,” linked a series of cultural landmarks immersed in festive ambiance. At Puyuan Fashion Ancient Town, the influencers marveled at the sweeping lantern displays, dazzling light installations, and strategically placed New Year decorations—while also bearing witness to the breathtaking spectacle of “Datiehua” (molten iron fireworks), an intangible cultural heritage performance that radiated both passion and romance, deeply rooted in traditional folk customs. On the iconic Yuehe Historical Street, home to distinctive attractions such as the Zongzi (rice dumpling) Museum, time-honored brands including Shendang rice wine and Weidefeng offered an authentic taste of local heritage. The bustling array of traditional New Year goods evoked cherished memories of a Jiaxing-style Spring Festival. Meanwhile, Nanhu Tiandi, Jiaxing’s most vibrant and trendy commercial district, has likewise embraced its festive transformation. Adorned with a series of celebratory art installations that seamlessly blend Jiangnan elegance with contemporary aesthetics, the area also hosts a lively New Year market running through the Lantern Festival. With photogenic scenes at every turn, the district embodies a stylish reinterpretation of traditional Chinese New Year spirit—where heritage meets modernity in the most captivating way. Encountering Ancient Jiangnan Towns: Immersing in the Slow Rhythms of Life Beyond the vibrant festive atmosphere, the influencers delved into Jiaxing’s rich tapestry of ancient cities and towns, exploring the city’s profound historical legacy across different eras and perspectives. At the Zicheng Archaeological Site Park, they wandered along the millennia-old city walls, listening to the silent stories embedded in every stone and experiencing the flow of Jiaxing’s history through centuries of change. Continuing to the Nanhu Tourist Resort, they ascended the iconic Misty Rain Pavilion against a backdrop of mist and drizzle, taking in sweeping views of Nanhu Lake and gazing upon the historic Red Boat—a timeless symbol enshrined in China’s revolutionary memory. At this convergence of red culture and Jiangnan scenery, they came to appreciate the city’s layered cultural identity. As night descended, an evening boat cruise offered a poetic conclusion to the day’s journey, weaving together the shimmering lights of Jiaxing’s waterfront. Gliding along the calm waters, the boat revealed a panorama of architectural silhouettes lining the shores—each telling its own story—unfolding like a living scroll of a “city that never sleeps,” both timeless and enchanting. “To Discover the Soul of Jiangnan’s Ancient Towns, Look to Jiaxing.” Xitang and Shendang unfold like two quietly turned pages from the chronicles of authentic Jiangnan life. Xitang Ancient Town, celebrated as a “living millennium-old town,” preserves remarkably intact clusters of Ming and Qing architecture, defined by its signature layout of “numerous bridges, winding lanes, and sheltered corridors.” Here, time seems suspended in a gentle, harmonious rhythm. Shendang Ancient Town, by contrast, offers a more tranquil and introspective experience. Largely untouched by excessive commercial development, it allowed the influencers to immerse themselves in the unspoiled, slow-paced essence of Jiangnan life. This journey by the Malaysian content creators stands as a vivid testament to Jiaxing’s cultural tourism vision—using the Spring Festival as a cultural bridge to share the refined aesthetics of Jiangnan with the world. Where time-honored New Year traditions converge with the legacy of ancient towns, and where revolutionary heritage intertwines with contemporary luminous artistry, Jiaxing reveals its uniquely inclusive and multifaceted character. It is crafting a fresh narrative for Spring Festival travel—one that blends festive richness with heartfelt experiences. Come, and discover a different kind of Jiangnan Chinese New Year.

Seattle, Washington – February 10, 2026 – (SeaPRwire) – Singer-songwriter Dr. Don has surpassed one million views on YouTube across three of his music videos in less than a year, marking a major digital milestone for the independent artist. The songs “Beautiful Vibes,” “Vodka Tonight,” and “Ruled by Time” have each crossed the seven-figure mark on the platform, with additional short-form video versions also reaching significant view counts. Dr. Don’s milestone highlights his rise as an independent artist, proving that multiple songs can attract large audiences without relying on traditional promotion. Strong performance across both full-length and short-form videos shows his ability to connect with listeners in different ways, marking a significant step in his career and illustrating how music can thrive organically in today’s digital landscape.  According to Dr. Don, “Ruled by Time” has become the strongest engagement anchor among the releases, continuing to generate repeat viewers, lyric-based comments, and ongoing discussion. He said the video has maintained active interaction well beyond its initial surge.  Dr. Don described “Ruled by Time” as a standout, noting its strong and sustained engagement. “It has become the strongest anchor among my releases. The video continues to show unusually high interaction with repeat viewers, lyric-based comments, and ongoing discussion,” he said. “Seeing people reference the lyrics and share their experiences shows the music is landing in a real way.”  The surge comes without a label machine, radio pipeline, or marketing firm behind it. Dr. Don is building this momentum on his own, releasing music independently and growing his audience one listener at a time.  Crossing the million-view mark across three separate songs in less than a year places him in rare company among truly self-directed artists. The numbers reflect not a campaign, but a connection, powered by repeat viewers, shared links, and sustained conversation around the music.  Each milestone strengthens his position as a solo creator proving that scale is still possible without gatekeepers. With multiple videos now hitting seven figures, Dr. Don is expanding his platform in real time, connecting with listeners globally while preparing his next projects. His work illustrates how focus, consistency, and authenticity can turn digital engagement into a tangible career milestone.  This is where music meets momentum. Visit Dr. Don’s official YouTube channel and follow him on social media for updates.  About Dr. Don  Dr. Don is a singer-songwriter and performer known for blending introspective lyrics, rich baritone vocals, and expressive movement to create immersive musical experiences. His work explores the complexities of human emotion, vulnerability, and personal growth. Beyond music, he draws on a background in law to inform his understanding of human behavior and storytelling, making each performance a unique reflection of artistry and self-expression.  Media Contact  Dr. Don  E: don@drdonmusic.com  W: https://drdonmusic.com/

Historic insurance partnership with Great American Insurance Group sets new standard for player protection KUALA LUMPUR, Malaysia – February 09, 2026 – (SeaPRwire) – playX today announced a milestone achievement in player protection, unveiling an industry-leading insurance policy secured through a strategic partnership with Great American Insurance Group (GAI), a trusted provider of gaming insurance solutions since 1995. The announcement was made during a special company event in Kuala Lumpur, highlighting playX’s continued commitment to strengthening financial safeguards for players across its platform. Official Video: https://www.youtube.com/watch?v=EpvceD-HJyU What This Means for Players The policy directly protects all playX players. If playX ever ceases operations, players can file claims directly with GAI to recover their funds — a first in online gaming history. Direct claim rights with Great American Insurance Group Platform insolvency protection for all player funds Backed by GAI’s 30-year track record in gaming insurance Guinness-verified player protection in online gaming “This isn’t just a title — it’s a guarantee that our players’ funds are protected by an independent, globally recognized insurer, not just our promises,” said Mark Carter, CEO of playX. About playX Premier online gaming platform serving Southeast Asia, combining cutting-edge technology with industry-leading security. About Great American Insurance Group Century-old insurance provider; Fidelity & Crime division has led gaming insurance since 1995. Official Channels Facebook: https://www.facebook.com/playX.my Instagram: https://www.instagram.com/playx.my/ Telegram: https://t.me/playXofficial YouTube: https://www.youtube.com/@playXOfficial8 Media contact Brand: playX Contact: Media team Email: marking@playxgaming.com Website: https://playx.my

New York, NY – February 01, 2026 – (SeaPRwire) – Recently, the world’s only Pokémon card graded PSA 10 – Pikachu Illustrator – once again became a focal point of global attention across the collectibles and cultural landscape. As a long-term contributor to TCG infrastructure and the broader collectibles ecosystem, The Collectors Grid(TCG.Zone) participated in and witnessed this historically significant moment. Recognized as one of the most iconic works in Pokémon card history, Pikachu Illustrator is distinguished not only by its extreme rarity, but also by its symbolic representation of Pokémon culture, artistic value, and generational memory. The Legendary Status of the World’s Only PSA 10 According to publicly available information, the world’s only PSA 10 “Pikachu Illustrator” card is currently owned by Logan Paul. The card was involved in a high-profile transaction in 2022, valued at nearly USD 5.3 million, marking a defining milestone in the history of Pokémon card collecting. The Industry Significance of Goldin Auctions Although Logan Paul’s acquisition of the card did not take place through Goldin, the Goldin auction platform has continued to play an important role in the card’s contemporary circulation and visibility. As one of the world’s most influential high-end collectibles auction platforms, Goldin’s auction framework and the attention it generates brought renewed global focus to this legendary card, further positioning Pokémon cards within the broader mainstream collectibles market. Netflix Documentary Captures a Cultural Moment Amid the phenomenon-level attention generated by this card on the Goldin platform, Netflix documented the full auction process and produced a dedicated documentary. Approached from a cultural and historical perspective, the documentary highlights the unique position of Pikachu Illustrator within the modern collectibles ecosystem, elevating it beyond price alone and framing it as a lasting cultural reference. Global Participation and TCG.Zone’s Involvement The discussions and auction activity surrounding Pikachu Illustrator attracted participation from top collectors, institutions, and professional teams from around the world. TCG.Zone was among the active participants in the bidding process. During the auction, TCG.Zone submitted a bid of USD 5,000,000. Although the bid was ultimately surpassed by a higher offer, TCG.Zone remained deeply engaged throughout the process and witnessed this pivotal moment firsthand. Continuing to Follow the Card’s Future Trajectory In post-auction interviews, TCG.Zone stated that this participation does not mark an endpoint. The team will continue to closely monitor the movement and future trajectory of the world’s only PSA 10 Pikachu Illustrator, and does not rule out participating again should the right opportunity arise. This event represents more than an auction. It stands as a collective reflection on rarity, cultural identity, and long-term value. The story of Pikachu Illustrator continues to unfold,and remains an enduring chapter in the global history of Pokémon card collecting. Social Links Twitter: https://x.com/tcgzoneofficial Instagram: https://www.instagram.com/tcgzoneofficial/ Telegram: https://t.me/tcgzoneofficial Media Contact Brand : The Collectors Grid (tcg.zone) Contact: Annie Email: hi@tcg.zone Website: https://www.tcg.zone

SHENZHEN, Jan 30, 2026 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received approval from the National Medical Products Administration of China (NMPA) on 30 January 2026 for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. It is the first and only targeted drug approved in China for vitiligo, addressing a significant unmet clinical need. Ruxolitinib phosphate cream is the first and only drug approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for repigmentation in nonsegmental vitiligo[1,2]. Prior to receiving formal NDA approval, the Group benefited from the “Early and Pilot Implementation” policy granted to the Hainan Free Trade Port and Lecheng Pilot Zone (“Lecheng Pilot Zone”), the “Hong Kong and Macau Medicine and Equipment Connect” policy, and the clinically urgently needed imported drug policies of the Beijing and Tianjin Free Trade Zones, and had already initiated the pilot application of ruxolitinib phosphate cream. Currently, Boao Super Hospital has prescribed ruxolitinib phosphate cream to over 7,000 patients with non-segmental vitiligo, and more than twenty hospitals in Guangzhou, Shenzhen, Dongguan, Foshan, Zhongshan, Zhuhai, Jiangmen, Huizhou, Beijing and Tianjin have provided prescription services for the Product, demonstrating its clinical potential. The product has shown positive results in both overseas clinical studies and the real-world study in China: in two identical Phase III double-blind, randomized, placebo-controlled studies (TRuE-V1 and TRuE-V2) conducted overseas, the proportion of patients achieving the primary efficacy endpoint of at least 75% improvement in the Facial Vitiligo Area Score Index (F-VASI 75) after 24 weeks of treatment with ruxolitinib phosphate cream was 29.9% in both studies, significantly higher than the 7.5% and 12.9% in the placebo groups, respectively. Continued use up to 52 weeks showed sustained repigmentation[3]. In accordance with the relevant regulations of the Lecheng Pilot Zone’s real-world data application pilot project, ruxolitinib phosphate cream underwent real-world study in China, demonstrating positive efficacy consistent with the results of overseas pivotal clinical studies. All secondary efficacy endpoints in both domestic and overseas clinical studies showed a benefit trend consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with prolonged treatment. Furthermore, according to safety monitoring data from the Lecheng Pilot Zone, no new safety event was identified, no adverse event (AE) leading to discontinuation or withdrawal of treatment occurred, and no study drug-related serious adverse event (SAE) occurred. This approval in vitiligo brings new hope for treatment to over 10 million vitiligo patients in China, addressing urgent clinical needs. At the same time, it will add to Dermavon’s product portfolio in the field of skin treatment, potentially synergizing with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon’s position in the field of skin health. Furthermore, the Phase III clinical trial in China of ruxolitinib phosphate cream for the treatment of mild to moderate atopic dermatitis (AD) has achieved positive results. Currently, the Group is actively advancing the NDA for ruxolitinib phosphate cream for the treatment of AD in China, which, if approved, will provide a new treatment option for a broader patient population with AD in China. About Vitiligo Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[4]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. The NDA approval of ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance. More About Ruxolitinib Phosphate Cream Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is approved for the topical treatment of nonsegmental vitiligo in adult and patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate AD in patients aged 2 years and older without immunodeficiency in the U.S. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. The Group, through a subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside Mainland China to the Group (excluding Dermavon and its subsidiary). Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development  of the Group. Reference: 1. The U.S. FDA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream 2. The EMA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar 3. The clinical studies information can be found on the Opzelura® official website, as follows: https://www.opzelura.com/opzelura-prescribing-information 4. China Insights Consultancy’s industrial report CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/

Moscow, Russia – January 31, 2026 – (SeaPRwire) – Expert Dialogues were held for the first time within the Open Dialogue framework at the Russia National Centre in Moscow on 30 January. The forum focused on five major megatrends shaping global economic, technological, and social development, bringing together international experts to explore how these forces will influence societies and industries in the decades ahead. Organized by the Russia National Centre in partnership with the Centre for Cross-Industry Expertise “The Third Rome” and supported by the Presidential Executive Office, the forum brought together experts from around the world to discuss economic, technological, and social transformations. Maksim Oreshkin, Deputy Head of the Russian Executive Administration for Global Trends, presented five key megatrends that, he said, are already shaping global development and will continue to influence the world in the coming decades. “By 2026, Open Dialogue has become an international platform uniting experts from across the world to discuss the future of the planet, the global economy, and society,” Oreshkin said. “Understanding these processes is essential for preparing for change and leveraging it in the interests of nations and, above all, people. Today, I will focus on five key megatrends — while not treating artificial intelligence as a separate trend, because it has already become an integral part of our lives.” 1. A New Global Economic Paradigm: Globalisation 2.0 A shift from traditional globalisation to a more decentralised system was described. BRICS+ countries now play a growing role in the global economy, technological development, and demographic trends, while the Global South is increasingly engaging in direct trade and national-currency settlements. “Globalisation hasn’t ended; it has changed,” Oreshkin said. “Sovereignty — at state, social, and economic levels — is now the key to competitiveness. Only countries that preserve all three levels can lead in a multipolar world.” China, the USA, India, and Russia are identified as major global powers, while highlighting emerging growth centres such as Indonesia and “connector countries” like the United Arab Emirates. Digital platforms and decentralised networks are also becoming independent participants in the world economy. 2. Platformisation and Institutional Automation The second megatrend highlights the rise of platforms and automation across all sectors. Platforms and algorithms are increasingly shaping decision-making in healthcare, education, finance, trade, and beyond. “Platform solutions enhance efficiency and reduce transaction costs through self-adjusting algorithms,” Oreshkin said. “Countries without technological sovereignty risk becoming dependent on external platforms, which can have strategic consequences during conflicts.” 3. Transformation of the Global Financial System It was noted that traditional financial models face mounting challenges, including rising public debt, widening inequality, and geopolitical fragmentation. Technologies such as blockchain, artificial intelligence, and digital platforms are creating alternative financial mechanisms, including decentralised finance. “The traditional model of cross-border payments is under pressure. Decentralised systems and digital technologies are reshaping the financial system,” he said. 4. Demographic Shifts and Challenges The fourth megatrend concerns global population dynamics. Global fertility rates have fallen sharply, with some countries facing critical declines. By the end of the 21st century, the working-age population may shrink significantly, while the proportion of elderly people rises, placing pressure on pension systems and social services. “Even in Africa, the ratio of elderly to working-age population will rise to 30%, and globally to 56%,” Oreshkin explained. “Education demand will decrease, but healthcare and social service needs will grow. These interconnected trends will amplify each other.” 5. Human Capital Development in the Technological Era The final megatrend focuses on human capital in a rapidly changing technological environment. Autonomous systems, digital platforms, and artificial intelligence are transforming education, work, and healthcare, while biotechnologies expand human capabilities. “AI is both a challenge and an opportunity,” Oreshkin said. “It allows personalized learning paths and supports teachers. Professions are changing: mid-level specialists will be in demand, and companies must retrain employees from junior positions. The social sphere will also evolve, ensuring active longevity in the new demographic era.” Global Perspective Throughout the presentation, Oreshkin illustrated each trend with real-life examples from different continents: a manager from Asia, a farmer from Africa, and a homemaker from Eastern Europe. He highlighted that innovations in Africa could improve education and healthcare, Eastern Europe may see rising living standards and more efficient social systems, and Asia will require reskilling to meet changing labor demands. “The world has entered a period of significant change in finance, demography, and other spheres. States, companies, and individuals must be prepared. Those who understand and adapt will shape the future,” Oreshkin concluded. Open Dialogue on Air This year, Open Dialogue introduced a podcast format — Open Dialogue on Air — featuring global experts discussing key trends in international development. Participants include award-winning Chinese sci-fi writer Chen Qiufan, Dr. Selina Neri of the Future Readiness Academy, Dr. Rais Hussin of EMIR Research (Malaysia), Prof. Wang Feng of UC Irvine, and global strategist Dr. Parag Khanna. First held in April 2025 at the Russia National Centre, the Open Dialogue brought together over 3,000 experts from dozens of countries. By presidential decree, it will now be held annually. Social Links Telegram: https://t.me/gowithrussia VK: https://vk.com/gowithrussia OK: https://ok.ru/gowithrussia DZen: https://dzen.ru/gowithrussia Contact for the media Brand: Russia National Centre Contact: Media team Email: Pressa@russia.ru Website: https://russia.ru Essay Submission: https://dialog.russia.ru/en/

In Collaboration with MAGO Moon Museum, Opening the “$VIVI RWA MARKET” Singapore – January 29, 2026 – (SeaPRwire) – LEGENDARY HUMANITY, a Singapore-based company listed on Gate.io, has announced the launch of the “$VIVI RWA MARKET,” a new Real World Asset (RWA) marketplace enabling the purchase of exhibited works by contemporary artist Mago Nagasaka. Developed in collaboration with the MAGO Moon Museum, this launch marks a significant milestone in LEGENDARY HUMANITY’s ongoing efforts to bridge cultural value and digital infrastructure through real-world assetization. Digitalizing Humanity’s Masterpieces Through AI 3D Scanning Technology – A New Purchasing Experience Led by LEGENDARY HUMANITY LEGENDARY HUMANITY PTE. LTD. (Headquarters: Singapore; CEO: Takamasa Suzuki) has officially opened the “$VIVI RWA MARKET,” an RWA marketplace where visitors can directly purchase artworks exhibited in the online museum “MAGO Moon Museum,” created by contemporary artist Shingo Nagasaka. This initiative forms part of the “VIVI PROJECT,” which aims to digitize humanity’s masterpieces into digital assets through high-precision, non-contact AI-integrated 3D scanning technology. Through this platform, visitors are able to acquire artworks they have viewed within MAGO Moon Museum as RWAs, enabling a deeper engagement with the artist’s worldview and creative philosophy. Overview Name: $VIVI RWA MARKET Opening Date: Thursday, January 29, 2026 URL: https://mondo.lhvivi.io/ About “$VIVI RWA MARKET” The “$VIVI RWA MARKET” is an RWA marketplace dedicated to the acquisition of artworks and is embedded within the online museum MAGO Moon Museum. Seamless Pathway from Viewing to Purchase Users can seamlessly transition from an artwork’s exhibition page to its corresponding RWA product page, creating a unified experience from online viewing to ownership. Integration of Physical and Digital Asset Design Each artwork includes the following structured information: Physical artwork details (size, materials, condition, provenance) High-resolution digital data generated through AI 3D scanning Artist profile and project background information along with other curated metadata. This structure allows users to acquire artworks with a proper understanding of their cultural and artistic value. Ecosystem Holding Functionality Acquired works will gradually gain viewing and management functionality within the VIVI ecosystem. While future integration with VIVI COiN is under consideration, the current initiative is focused solely on enhancing the preservation, appreciation, and understanding of the artworks. About LEGENDARY HUMANITY and the VIVI PROJECT LEGENDARY HUMANITY promotes the “VIVI PROJECT,” which digitizes legendary masterpieces created by humanity into digital assets using high-precision, non-contact, AI-integrated 3D scanning technology. The project operates under the vision of “Bringing the beauty of humanity to AI and the future.” Targeted assets include: Legendary fashion collections Historical architecture and cultural masterpieces Famous trading cards Artworks, including those exhibited at MAGO Moon Museum and other assets that can be described as humanity’s masterpieces. The VIVI PROJECT aims to: Digitize assets as digital cultural heritage Tokenize them as RWAs for global circulation Exhibit them in both online and physical museums thereby building new infrastructure that harmonizes cultural and economic value. NEXT SOCIETY (Gacha Location): https://nextsociety.lhvivi.io RWA Market Roadmap The launch of the “$VIVI RWA MARKET” represents the first phase of RWA market functionality within the VIVI PROJECT. Planned future developments include: VIVI FASHION (RWA for the fashion domain) VIVI TRADING CARD (RWA for the trading card domain) VIVI ART WORK (RWA for art collections) with future integration under consideration. About MAGO Moon Museum MAGO Moon Museum is an online museum created by contemporary artist Shingo Nagasaka, whose works explore themes related to electronic waste issues in Agbogbloshie, Ghana. The museum provides an online space to view Nagasaka’s representative works, including pieces created from discarded electronic components found in Ghanaian slums, as well as series examining the concept of “Sustainable Capitalism.” With the implementation of the “$VIVI RWA MARKET,” viewers can deepen their understanding of the artworks while acquiring pieces aligned with the artist’s philosophy in an appropriate and structured manner. Future Developments Building on this initiative, LEGENDARY HUMANITY plans to: Expand collaborations with masterpieces across different regions and genres Strengthen international networks with artists, collectors, and researchers Advance technological development for the preservation of cultural assets for future generations and continue developing as a platform that passes humanity’s masterpieces into the future through real-world assets. Media Contact Company Name: LEGENDARY HUMANITY PTE. LTD. Address: 105 Cecil St, The Octagon 24F-2, Singapore 06953 Representative: Takamasa Suzuki, LEGENDARY HUMANITY / VIVI PROJECT Public Relations Desk Email: info@lhvivi.com Related URL: $VIVI RWA MARKET https://mondo.lhvivi.io

Commences building an RWA (Real-World Asset) token economy Maximizing Value Through Digitalization Using Cutting-Edge 3D Scanning Technology “SCAI” and RWA Indexing New York, NY – January 20, 2026 – (SeaPRwire) – VIVI PROJECT (formerly LEGENDARY HUMANITY) announces a major update and rebranding. The project utilizes the latest 3D scanning technology “SCAI” to digitally archive humanity’s cultural heritage, providing training data for AI and building a new token economy based on RWA (Real World Assets). Background and Project Evolution Previously, “LEGENDARY HUMANITY” aimed to digitize humanity’s greatest masterpieces using cutting-edge technology, teaching AI about “humanity’s magnificence” to preserve its value for future generations. With this update, the project is renamed “VIVI PROJECT.” Moving beyond mere archiving, it will challenge the creation of new value in the Web3 era as an “RWA token project” building a unique economic ecosystem backed by real-world assets (RWA). The Four Pillars of the “RWA Ecosystem” Provided by VIVI PROJECT Digitization via High-Precision 3D Scanning Technology “SCAI:DIGITAL LUMINOUS Technology” Digitizing humanity’s treasures and providing them as AI training data. Merging human wisdom with technological evolution. Adding RWA Value to VIVI COiN: Centered around the project token “VIVI COiN,” we plan to link RWA held by collectors partnered with “VIVI PROJECT” to enhance the project’s value.By using “LEGENDARY masterpieces” whose value appreciates over time as the foundation for “VIVI COiN,” we build a stable value base. Hybrid Digital & Physical Museum Collected RWAs will be displayed in both digital museums and physical exhibition facilities. Trading via the marketplace will also be enabled, enhancing liquidity as an asset. VIVI DAO’s “Buy-Back & Burn” Model The governing body, “VIVI DAO,” will use exhibition and sales revenue to implement “Buy-Back” and “Burn” of VIVI COiN. This will increase the token’s scarcity and promote long-term value appreciation. Future Outlook: Global Collection Partnerships The VIVI PROJECT is advancing the networking of collections held by global asset owners. As a first step, we have initiated the following partnerships and negotiations: LA MUSEUM: Holds one of the world’s largest legendary fashion collections, including Yves Saint Laurent, Comme des Garçons, Worlds End, Alexander McQueen, John Galliano, and Madison Martin Margiela. Major Trading Card Company: Negotiations have commenced with the world’s largest trading asset company. This will integrate Real-World Assets (RWAs) from diverse genres like fashion, art, and hobbies into the project, rapidly expanding the ecosystem. VIVI PROJECT Overview VIVI PROJECT is a next-generation platform that preserves and utilizes humanity’s greatest masterpieces in both digital and physical realms through the fusion of culture and technology. By indexing RWA, it defines new asset value in the Web3 era. Official Website: https://lhvivi.com Contact for Inquiries Contact: VIVI PROJECT PR Department Email: press@lhvivi.com

Riyadh, Saudi Arabia  - 2026年1月18日 - (SeaPRwire) - 昨晚（週六），第六屆歡樂獎2026在利雅得隆重舉行。本次活動隸屬於“利雅得季”，由沙烏地阿拉伯總娛樂管理局主辦，並與中東廣播中心建立戰略合作夥伴關係。儀式在總娛樂管理局主席圖爾基·阿勒謝赫閣下的出席下舉行，彙聚了來自電影、電視劇、音樂、體育及數字內容領域的阿拉伯及國際頂級人物，現場媒體關注度極高，公眾互動熱烈。 頒獎典禮通過多個電視頻道進行現場直播，並在數字平臺同步播出。觀眾從明星們踏上薰衣草色地毯的瞬間開始，全程關注了包括獎項頒發、榮譽表彰以及多段現場音樂和表演在內的完整娛樂盛典。 當晚在充滿節慶氛圍的環境中拉開序幕，藝術家和名人陸續抵達，現場媒體對明星首次亮相給予了高度關注。隨後，圖爾基·阿勒謝赫閣下抵達現場，成為官方節目開始前的重要時刻。沙特國歌奏響後，典禮進入震撼的開場娛樂表演。 世界知名歌手凱蒂·佩裏獻上獨具特色的開場演出，表演融合了交響樂元素、舞者與視覺特效，通過動態燈光與強烈的舞臺表現力，呈現出高度製作化的藝術畫面，充分體現了本屆活動的規模與精密籌備。 隨後，國際表演團體皮洛博魯斯帶來影子舞表演，以創新且節奏輕快的視覺形式重新吸引觀眾注意力。接著，頒獎環節依照流程正式展開，現場嘉賓與媒體在結果揭曉前充滿期待。 拉贊·賈邁勒與梅娜·沙拉比共同頒發“最受歡迎電視劇男演員獎”。提名者包括《阿什拉街》的阿蔔杜勒拉赫曼·本·納菲亞、《碼頭》的阿蔔杜勒莫赫森·納默、《呼吸》的穆塔塞姆·納哈爾，以及《非常擁擠的公寓》的希沙姆·馬吉德。最終，阿蔔杜勒莫赫森·納默榮獲該獎項。 隨後，圖芭·比尤克烏斯滕與哈利特·埃爾根奇頒發“最受歡迎黎凡特地區電視劇獎”。入圍作品包括《阿塞爾》《血之中》《七層之下》和《薩爾瑪》，最終《薩爾瑪》獲獎，劇組成員登臺領獎。 在終身成就獎特別環節中，圖爾基·阿勒謝赫閣下親自表彰埃及著名畫家、前文化部長法魯克·胡斯尼，以表彰其長期以來的藝術成就與文化貢獻。閣下表示能親自授予這一榮譽深感榮幸，胡斯尼則對沙特王國、其領導層及閣下本人表達了由衷感謝。 “最受歡迎新晉電視劇明星獎”由麥·奧馬爾與穆罕默德·薩米頒發。提名者包括《我的母親》的塔拉夫·奧拜迪、《薩爾瑪》的羅西爾·易蔔拉欣、《無陽光》的阿裏·拜亞利，以及《阿什拉街》的拉瑪·阿蔔杜勒瓦哈蔔。最終，塔拉夫·奧拜迪獲得該獎項。 隨後，音樂表演再次成為焦點，安甘與波蘭吉他演奏家馬爾欽同台獻藝，現場互動熱烈。典禮繼續進行，由穆罕默德·亨迪迪頒發“最受歡迎海灣地區電視劇獎”，《碼頭》《我的母親》《阿什拉街》《劍99》入圍，最終《阿什拉街》獲獎。 “最受歡迎電視劇女演員獎”由巴裏什·阿爾杜奇與漢德·埃爾切爾頒發。提名者包括《我的母親》的阿拉努德·蘇歐德、《阿什拉街》的伊勒哈姆·阿裏、《無陽光》的阿米娜·哈利勒，以及《七層之下》的卡麗絲·巴沙爾。最終，卡麗絲·巴沙爾獲獎。 “最受歡迎埃及電視劇獎”由李秉憲與李政宰共同頒發，入圍作品包括《伊什·伊什》《非常擁擠的公寓》《艾莎的房間》《無陽光》，最終《非常擁擠的公寓》榮獲該獎。 Media contact Brand: Legends PR Contact: Media Center Email: PR@legends.sa Website: https://legends.sa

Mexico City, Mexico – January 10, 2026 – (SeaPRwire) – Excent Capital has announced the launch of a new incentive program for its global partner network, offering exclusive experiences connected to the 2026 World Cu as part of its ongoing commitment to long-term collaboration and partner engagement. The initiative is designed to recognise partner performance and strengthen relationships through experiences that go beyond traditional rewards. Depending on performance tiers, partners may qualify for packages that include match tickets, travel arrangements, accommodation, and curated experiences in the United States during the tournament. Rather than focusing solely on volume, the program is structured to encourage sustainable growth, strategic alignment, and continued collaboration between Excent Capital and its partners. The incentive tiers are linked to clearly defined performance benchmarks, ensuring transparency and consistency across regions. “We work very closely with our partners on a daily basis, and this initiative is a way to give something back that goes beyond numbers,” said Andrés Espinosa, Senior Business Development Manager at Excent Capital. The World Cup 2026 incentive program is open to eligible partners worldwide and will run until May 15. Participation details, performance criteria, and tier qualifications are communicated directly to partners through Excent Capital’s regional business development teams. About Excent Capital Excent Capital is a global trading broker offering access to a wide range of financial markets. Operating on proprietary, in-house developed technology, the company focuses on transparency, execution quality, and partner-driven growth, supporting partners through education, consistent market insight, and collaborative initiatives. Contact Information Organization: Excent Capital Contact Person: Ryccielli Ongaratto, Marketing Manager Email: support@excent.capital Website: https://excent.capital/

香港 - 2026年1月5日 - (SeaPRwire) - Web3 的大規模採用，並不是通過更響亮的敘事或更鋒利的口號實現的。它往往是悄然發生的——依託於逐漸隱形的基礎設施，在後臺無縫支撐人們的日常數字行為。而這一拐點，或許比許多人預期的更近。 iMe 是一款基於 Telegram 的超級應用，融合了即時通訊、AI 交互與去中心化金融（DeFi）。目前，iMe 在 Google Play 和 App Store 的累計下載量已突破 1700 萬。其最新發佈的 iMe Wallet 2.0 並不僅僅是一次版本升級，而是一次關於 Web3 交付方式的戰略性轉變。 iMe 並未將加密貨幣塑造成一種“獨立體驗”，而是通過 Telegram Mini App（TMA），將 Web3 功能直接嵌入 Telegram。本身。使用者無需離開日常使用的聊天介面，就能與數位資產、DeFi 工具以及 AI 輔助工作流進行交互。無需額外下載應用，也無需面對陌生的用戶體驗，更不會出現刻意的“進入加密世界”的時刻。 在 Telegram 全球用戶數逼近 9 億的背景下，僅這一分發入口本身就代表著一次重大的規模化突破。但真正的關鍵，在於支撐 iMe 下一階段增長的底層基礎設施。 Attractor：為規模化社區打造的原生 Layer 2 支撐 iMe 擴張的是 Attractor —— 一個正在開發中的區塊鏈專案，致力於構建以 zk-rollup 為核心的 Layer-2 網路，其設計目標並非服務小眾的 DeFi 高階用戶，而是面向龐大且高速增長的社區型應用。 與那些主要為單一金融協議優化的通用 Layer-2 不同，Attractor 專為消息、支付、自動化和 AI 交互需要在互聯網規模下即時、低成本、無感運行的場景而生。 Attractor 的核心架構特性包括： 零知識rollup 架構，在保持 Ethereum 級安全性的同時實現高輸送量 超低交易費用，使面向大眾的微交互在經濟上可行 支持Account Abstraction 的設計，消除助記詞等使用門檻，實現接近 Web2 的用戶體驗 原生支援AI 驅動邏輯，使自動化與 AI agents 能夠直接在鏈上運行 以社區為中心的網路模型，專為服務數百萬使用者的應用進行優化 在Layer-2 網路上線後，從 ERC-20 向原生 Attractor 網路無縫遷移的路徑 這並不是為投機而打造的基礎設施，而是為已經被真實使用者使用的產品而構建的。 ATTRA Token 正式上線 Attractor 已完成其原生代幣 ATTRA 的 Token Generation Event（TGE）。目前，ATTRA 已作為 ERC-20 資產在去中心化交易所上線。團隊已確認，在 Attractor Layer-2 主網上線後，ATTRA 將遷移至原生網路，從而在整個生態系統中釋放完整的協定級效用。 這種“先流動性、後基礎設施、再生態擴展”的分階段路徑，與迄今為止最成功的 Layer-2 專案高度一致。更重要的是，它將代幣價值與真實產品使用深度綁定，而非依賴投機性敘事。 為什麼這一時刻至關重要 這是 Web3 發展史上，首次在同一套完整技術棧中同時彙聚三大關鍵要素： 通過Telegram 與 iMe 實現的大規模分發 借助AI 驅動、用戶友好交互實現的高度抽象 通過為大眾參與而定制的zk-rollup Layer-2 實現的可擴展性 在這一模式下，使用者並不是“進入 Web3”，而是直接使用解決方案。區塊鏈成為看不見的後臺，而非用戶感知的終點。 如果這一模式成功，iMe 與 Attractor 的協同關係將代表 Web3 增長方式的一次結構性轉變：安靜、原生、並以互聯網規模展開。不是通過教育用戶或強迫行為改變，而是通過表面熟悉、底層去中心化的產品自然發生。 這不是漸進式改良，而是那種在歷史上往往預示著指數級採用的基礎設施級對齊。而如果歷史經驗仍然適用，最具顛覆性的技術，往往不是最喧嘩的——而是那些幾乎不被用戶察覺的存在。 媒體聯繫 Email: Info@attra.me Website: www.Attra.Me

New York, NY – December 26, 2025 – (SeaPRwire) – Taxinexo, a U.S.-based autonomous vehicle operator, has entered a new phase of large-scale commercial deployment after nearly five years of continuous operation in the United States. Leveraging its mature Level 4 autonomous driving technology and proven operational capabilities, the company has expanded multi-scenario services across several U.S. states, positioning itself as a representative case of how federal and state policy coordination is accelerating the commercialization of autonomous driving in the U.S. smart mobility sector. Since its inception, Taxinexo’s growth trajectory has been deeply intertwined with the US autonomous driving industry’s policy support system. The US federal government, through national strategic documents such as the Comprehensive Autonomous Vehicle Initiative, has established a development orientation of “safety first, encouraging innovation,” providing companies with a flexible regulatory environment—including simplified administrative exemption procedures for autonomous vehicles, allowing steering wheel-less and pedal-less vehicles that meet technical standards to be tested and operated on public roads, significantly lowering the policy threshold for companies to iterate their technology. Meanwhile, the Inflation Reduction Act’s tax credit of up to $7,500 per vehicle for Level 3 and above autonomous driving vehicles further assisted Taxinexo in completing its R&D investment and fleet expansion, enabling it to achieve large-scale commercial operation in multiple states across the US. This has allowed it to accumulate millions of kilometers of real-world road operation data and build an operational network covering diverse scenarios such as urban main roads, business parks, and commuter shuttles. In an interview with this newspaper, Taxinexo’s Global Marketing Head stated, “The policy support in the US over the past five years has provided us with an excellent development platform. From technology R&D to commercialization, the flexible regulatory environment and precise policy support have allowed us to accumulate core capabilities to handle complex scenarios. In the future, we will continue to leverage local policy advantages, deepen our diversified scenario operation layout, and help promote the US autonomous driving industry towards a more efficient and safer stage.” Data shows that the US autonomous driving industry is rapidly expanding, with leading companies continuously increasing their fleet sizes and weekly order volume exceeding hundreds of thousands, indicating a broad commercial prospect for the industry. Taxinexo reportedly plans to further expand its service coverage in the United States based on its existing operations, focusing on high-frequency travel scenarios such as airport shuttles and intercity commuting, and will continue to increase investment in technology research and development to promote the iterative upgrade of its autonomous driving system. In the future, its large-scale operational experience may provide a replicable practice model for the intelligent transportation upgrades of more cities in the United States. Social Links Telegram: https://t.me/taxinexo X: https://x.com/taxinexo Facebook: https://www.facebook.com/profile.php?id=61585301312596 Instagram: https://www.instagram.com/taxinexo LinkedIn: https://www.linkedin.com/company/taxinexo/ YouTube: https://www.youtube.com/@taxinexo Media contact Brand: Taxinexo Contact: Media team Email: support@taxinexo.com Website: https://www.taxinexo.com

The King of the Monsters Becomes a Cinematic Welcome and Farewell, Showcasing Japanese Entertainment to Millions of International Travelers at Japan’s Global Gateway Singapore – December 23, 2025 – (SeaPRwire) – The HANEDA GODZILLA GLOBAL PROJECT officially launched a mega-scale initiative to broadcast Japanese entertainment to the world from Haneda Airport, through the collaboration of three companies: Toho Co., Ltd., Japan Airport Terminal Co., Ltd., and Tokyo International Airport Terminal Corporation. Under the theme “Godzilla welcomes all visitors to Japan and sees them off as they depart,” a colossal Godzilla statue, approximately 40 meters long and 9 meters tall, has been revealed inside Japan’s international gateway at Haneda Airport Terminal 3. Modeled after the original Godzilla, the monument surpasses the size of existing indoor installations and is designed to be viewed from multiple angles throughout Terminal 3. Additional installations in the area include Godzilla: The Great Monster Advance Picture Scroll in the arrival lobby and a standing statue from Godzilla Minus One that will be installed on December 3, further expanding the presence of the popular monster across arrivals and departures. To commemorate the completion of the world’s largest indoor Godzilla monument, a special announcement event was held at Haneda Airport, featuring remarks from notable guests. This consisted of Keiji Ota, Senior Managing Executive Officer and Chief Godzilla Officer (CGO) of Toho Co., Ltd.; Masatoshi Akahori, President and Representative Director of Tokyo International Air Terminal Corporation; and special guest actress Riko Fukumoto, ambassador for the “Godzilla The Ride” attraction at Seibuen Amusement Park. All of the guest speakers reflected on the cultural significance of the six-year project and Godzilla’s role as a global symbol of Japanese entertainment. As travel ramps up for the new year, the HANEDA GODZILLA GLOBAL PROJECT is set to leave a lasting impression on millions of international travelers passing through Terminal 3 with an encounter with one of Japan’s most iconic cultural symbols. The completion announcement event was held on Friday, December 19, with public installations opening in conjunction with year-end and New Year travel, and additional displays debuting beginning December 23. The unveiling was held at Haneda Airport Terminal 3 in Tokyo, Japan spanning both the departure and arrival lobbies at Japan’s primary international gateway. About TOHO Co., Ltd. TOHO Co., Ltd. is a leading Japanese entertainment company founded in 1932.  Its four main business pillars are the cinema business, which includes production, distribution and exhibition; the theatrical business, which includes production and exhibition; the anime business, which has been expanding globally in recent years; and the real estate business, which focuses on development in urban areas. TOHO’s worldwide acclaimed works include theatrical films such as the “Godzilla” series and “Seven Samurai” directed by Akira Kurosawa, and TV anime series such as “My Hero Academia” and “Jujutsu Kaisen”. These anime series are produced and distributed through the TOHO animation label, and are delivered to a wide range of audiences around the world. Media Contact TOHO Entertainment Asia hello@tohoea.com.sg

New York, NY – December 23, 2025 – (SeaPRwire) – Holiverse, a biotech platform, has begun active development of a decentralized AI device designed to operate entirely offline without cloud dependency. The device will embed private artificial intelligence directly on hardware, eliminating the need to transmit personal data to external servers. According to the company, this approach addresses growing concerns about data sovereignty, privacy erosion and the concentration of AI processing power in centralized platforms. “We have conflated intelligence with centralization,” said Lado Okhotnikov, founder of Holiverse. “We built these vast, brilliant minds and asked them to solve our problems. But in doing so, we outsourced our sovereignty.” The Holiverse decentralized AI initiative targets three key capabilities: On-device processing: All data remains in a closed loop on the user’s hardware Offline functionality: Intelligence operates without internet connectivity Hyper-personalization: Models tuned to individual biological and behavioral data “This is undoubtedly a complex and resource-intensive process, and we are engaging some of the leading AI specialists,” Okhotnikov added. “This technology has the potential to significantly reduce the risks associated with AI and make interaction with it truly personal.” Holiverse expects to present initial developments publicly in the coming months. About Holiverse Holiverse is a biotech platform that integrates human biology and advanced technology. Founded by Lado Okhotnikov, the company creates holistic health solutions through personalized, data-driven approaches. Learn more at holiverse.ai. Social Links X: https://x.com/Holiverse Telegram: https://t.me/holiverse_ENG Media Contact Brand: Holiverse Contact: Media team Email: mailbox@holiverse.ai Website: https://holiverse.ai

Seoul, Korea – December 23, 2025 – (SeaPRwire) – HTM Korea, a Korean fire-safety technology company, announced the global expansion of its innovative automatic fire-suppression product line, CERA+, designed to prevent electrical fires in outlets and distribution boards. The company has rapidly grown within the domestic market through public procurement channels, supplying products to government agencies, educational institutions, and major industrial clients. CERA+ is a compact fire-suppression patch that activates automatically when an electrical hotspot occurs. Containing a certified clean-agent extinguishing compound, the patch bursts at a specific temperature and releases the agent to suppress flames at the earliest stage. The product has received official KFI (Korea Fire Institute) type approval, along with reliability tests such as temperature, humidity, and durability evaluations. HTM Korea currently offers outlet-type patches and distribution-board models in 20L, 40L, and 80L capacities. The company is accelerating its entry into Southeast Asia, the Middle East, and the United States, supported by growing demand from data centers, residential complexes, and industrial facilities. “As electrical fire risks continue to rise worldwide, we aim to provide simple but highly effective protection that any facility can adopt easily,” said a company representative. “We will continue expanding our product line and strengthening global partnerships.” Media contact Company: HTM Korea Co., Ltd. Contact: Su Hyeon Oh Phone: +82-10-3504-2913 Email: cera@cera.krWebsite: https://www.cera.kr

Seoul, Korea – December 23, 2025 – (SeaPRwire) – The Third Market Co., Ltd. has opened Korea’s first Experiential Refurbished Electronics Showroom, a space where customers can directly test, compare, and verify refurbished electronics with full transparency. The showroom was created to solve long-standing consumer concerns around inconsistent quality and unclear product history in the refurb market. The Third Market manages the entire process in-house, including inspection, grading, labeling, and warranty issuance. Visitors can observe real-time inspection, review visualized product reports, and experience devices firsthand—shifting refurbished products from “low-cost alternatives” to “value-verified choices.” The showroom integrates an inspection center, exhibition zone, and logistics area, enabling seamless processing from intake to purchase. With its internal branding and design team, Third Market provides standardized labels, branded packaging, and expert consultations to enhance consumer trust. A dedicated Small Business Pop-Up Zone also supports local merchants by offering a new retail channel for overstock and returned goods, contributing to a healthier refurb ecosystem. “Our goal is to establish a new standard of trust in refurbished electronics,” said CEO Sang-ho Yoo. “Customers should be able to see exactly how products are evaluated and feel confident in their value.” The Third Market plans to expand additional hubs, enhance automated inspection technology, and strengthen global partnerships as it shapes the future of the refurbished electronics market. Media contact Brand: The Third Market Contact: Sang-ho Yoo Phone: +821041143582 Email: biz@ttm.imWebsite: https://shop.ttm.im

Singapore – December 22, 2025 – (SeaPRwire) – Asia Pricing Professionals (APP), the leading pricing and commercial excellence community in Asia-Pacific, today announced a major expansion of its professional development, certification, and community platform for 2026. The expanded portfolio positions APP as the region’s most comprehensive ecosystem for pricing, value management, and revenue excellence. Central to the 2026 expansion is a strategic partnership with the Professional Pricing Society (PPS), connecting global best practices with regional execution to support individuals, teams, and organizations as pricing evolves into a strategic, AI-enabled business capability. Comprehensive Pricing Training & Global Certifications From 2026, APP members will gain access to 100+ on-demand pricing courses through its collaboration with PPS, covering the full pricing and monetization lifecycle — from foundational principles to advanced real-world application. The curriculum spans: Pricing strategy and value creation Pricing analytics and data-driven decision-making Execution, governance, and price realization Negotiation and deal pricing SaaS and XaaS monetization models AI-enabled pricing and advanced analytics Organizational design and change management In addition, APP will offer globally recognized certifications, including the Certified Pricing Professional (CPP®) designation — the only worldwide credential synthesizing the art and science of pricing — and a new AI Pricing Certification, designed to help professionals apply artificial intelligence responsibly and effectively in pricing, forecasting, and commercial decision-making. Two Flagship APP Conferences in Singapore (2026) As part of its expanded offering, APP will host two one-day flagship conferences in Singapore in 2026, bringing together senior pricing, commercial, and revenue leaders from across Asia-Pacific. APP Conference 1 5 March 2026 | Singapore Theme: Smart Value: AI and the Future of Pricing & Revenue Growth The conference will explore how AI, analytics, and advanced pricing capabilities are transforming value creation, pricing decisions, and sustainable revenue growth. Key topics include AI-driven pricing, predictive analytics, price corridors, deal pricing, execution excellence, and ethics and governance in AI-enabled pricing. APP Conference 2 15 October 2026 | Singapore Theme: Total Revenue Excellence: Integrating Pricing, Profitability & Commercial Performance This event will focus on breaking organizational silos between Pricing, Sales, Finance, Revenue Management, and Commercial Operations to drive end-to-end revenue and profit performance. Key topics include deal desk design, discount discipline, KPI alignment, commercial operating models, and scaling revenue excellence across regions. Face-to-Face Training & Regional Networking Immediately following each conference, APP will deliver in-person, instructor-led training programs in Singapore on 6 March and 16 October 2026. These hands-on sessions focus on applied execution and advanced case work, and both count toward CPP® certification credits. In the second half of 2026, APP will also launch its “Five Big Cities” Networking Tour, with events planned in: Bangkok Jakarta Manila Shanghai Singapore Each event will feature curated networking, practitioner roundtables, and thought leadership discussions, strengthening APP’s role as a regional connector between local markets and global best practices. An Integrated Pricing Ecosystem for Asia-Pacific Together, APP’s training, certifications, conferences, live programs, and regional networking form a single integrated ecosystem designed to: Build pricing and commercial capability at scale Bridge theory with real-world execution Support career progression and organizational maturity Advance ethical, data-driven, and AI-enabled pricing across Asia-Pacific About Asia Pricing Professionals (APP) Founded in 2010, Asia Pricing Professionals is a not-for-profit community dedicated to advancing pricing, value management, and commercial excellence across Asia-Pacific. APP connects practitioners, leaders, and organizations through education, certification, events, and peer collaboration. Social Links LinkedIn: https://www.linkedin.com/groups/3813123/ Instagram: https://www.instagram.com/asiapricingprofessionals Media contact Brand: Asia Pricing Professionals Contact: Media team Email: deepaksood@asiapricingprofessionals.org Website: https://asiapricingprofessionals.org

【2025年12月19日】—— 光子易（PhotonPay） 宣佈上線新一代金融操作系統（Financial Operating System），完成其支付性能的又一次變革性提升。此次升級旨在最大限度簡化資金工作流，降低用戶操作成本，爲企業進行全球化擴張減少運營摩擦和支付卡點。 作爲由AI驅動的全球金融基礎設施提供商，光子易（PhotonPay）一直致力於攻克企業在當前跨境業務中普遍面臨，諸如財務系統割裂、支付成本高昂及管理複雜等痛點、難點。本次升級通過技術重構，在用戶端爲企業呈現一覽無遺的清晰資產視圖，增強企業對財務的掌控力。 重塑交互：高度靈活的定製化架構 新系統引入高度靈活的小組件（Widget-based）架構，支援用戶構建完全定製化的主頁。藉助直觀的拖拽功能，企業能夠根據自身特定的運營工作流調整界面佈局，將最關鍵的功能模組置於核心位置，實現操作效率的顯著提升。用戶操作頁面可展示前三高頻交易幣種匯率，並設定金融日曆同步提醒休市安排，避開交易空窗期。此外，頁面針對用戶常用核心功能，增加引導式氣泡提示，幫助用戶快速熟悉新版本操作。 全景洞察：數據驅動的決策中樞 數據可視化是此次更新的核心亮點。全新的「概覽頁面」爲企業提供「單一全景視圖」，透過聚合實時數據，實現對全球收付款的一站式監控與管理。升級後的系統配備動態圖表功能，可追蹤長達90天的現金流趨勢，幫助財務團隊掌握資金狀況，做出流動性決策。 以AI賦能：自動化高摩擦工作流 本次升級後的統一儀表板深度集成全球收單（Global Acquiring）、全球賬戶（Global Accounts）、全球付款（Global Payouts）、光子卡（PhotonPay Card）、匯率管理（FX Management）光子易五大核心模組。除可視性大幅提升外，升級版系統採用了由 AI驅動的全新UI/UX 設計，優先解決高頻、高摩擦工作流的自動化問題： 動態發卡： 精細化支出控制——包括單筆交易、每日及每月限額，發卡即刻生效，實現精準的費用管理。 優化批量付款： 透過AI驅動的智能驗證簡化大規模支付，系統可自動檢查批次檔案並標記潛在錯誤，確保支付執行的無縫與準確。 集中收款人管理： 安全存儲交易對手方/供應商信息，有效規避因人工錄入數據造成的錯誤。 簡化對賬流程： 管理多團隊、多幣種的交易明細，確保對全球資金流向的全面監管。 「此次升級不僅僅是我們操作系統的迭代，更是光子易在發展歷程中取得的一個關鍵技術性突破」 PhotonPay 光子易創始人兼 CEO 陳敏（Lewison Chen）表示，「我們的目標是消解金融複雜性，讓企業在出海業務中掌握更多自主權，幫助企業重塑跨境支付流程，賦能企業緊抓全球擴張的新機遇。」 面對複雜的全球金融支付環境，市場對統一支付解決方案的需求日益強勁：企業不再尋求單一的支付工具，而是需要一個覆蓋收單、付款及支出管理全生命週期的綜合金融操作系統。爲企業打造健康、可持續的支付生態，這正是光子易核心競爭優勢的關鍵所在。 以合規爲基石，光子易正透過技術重構金融服務，讓每一筆全球交易都成爲值得信賴的對話。   關於光子易（PhotonPay） 成立於 2015 年，PhotonPay 光子易是一家 AI 驅動的金融基礎設施平台，致力於為全球經濟構建數字支付網絡。PhotonPay 在全球設有11個辦事處，業務覆蓋超過 200 個國家和地區，賦能企業實現高效、安全且一體化的全球增長。

HONG KONG, December 19, 2025 – PhotonPay, an AI-powered global financial infrastructure provider, today announced the launch of its next-generation Financial Operating System. This transformative upgrade is engineered to minimize operational friction and streamline complex workflows for businesses expanding globally. Targeting the mounting costs and complexity of disconnected financial systems, the upgrade is engineered to deliver enhanced clarity and control. The new system introduces a highly flexible, widget-based architecture, allowing users to build a bespoke homepage. With intuitive drag-and-drop capabilities, businesses can now tailor their interface to match their specific operational workflows, placing critical functions exactly where they are needed. Data visibility is paramount in the new update. The Overview Page offers businesses a "single pane of glass" view, aggregating real-time data to provide clear, one-stop control over global pay-ins and payouts. The upgraded system also features dynamic charts tracking 90-day cash flow trends, empowering finance teams to make informed liquidity decisions at a glance. This unified dashboard integrates real-time insights across PhotonPay’s key modules:  Global Acquiring Global Accounts Global Payouts PhotonPay Card FX Management Beyond visibility, the upgrade features a brand-new UI powered by AI. This combination enables the new operating system to prioritize the automation of high-friction workflows: Dynamic Card Issuance:Delivers granular spending controls—including per-transaction, daily, and monthly limits—available immediately upon issuance for precise expense management. Optimised Bulk Payouts:Streamlines mass payments via AI-driven validation, automatically checking batch files to flag errors and ensure seamless, error-free execution. Centralised Payee Management:Securely stores vendor details to prevent errors caused by manual data entry. Streamlined Reconciliation: Uses a no-code interface to easily manage multi-entity, multi-currency transaction details, ensuring full oversight of global financial flows. "This upgrade represents more than just an iteration of our operating system; it is a pivotal milestone in PhotonPay's journey," said Lewison Chen, Founder & CEO of PhotonPay. "Our goal is to dissolve financial complexity and, more importantly, to democratise finance—putting control firmly back in the hands of our customers, empowering enterprises to seize new opportunities for global expansion." The market's demand for a unified solution is evident. Over the past year, the number of clients adopting multiple PhotonPay products has increased by more than 30%. This growth validates a key shift in the increasingly decentralised global landscape: businesses no longer seek standalone payment tools, but rather a comprehensive financial operating system covering the full lifecycle of pay-ins, payouts, and expense management. This evolution underscores precisely where PhotonPay is cementing its core competitive edge. With compliance as its cornerstone, PhotonPay is reconstructing financial services through technology—making every global transaction a trusted conversation.   About PhotonPay PhotonPay, an AI-powered financial infrastructure, was launched in 2015. Supporting over 10 global offices and operations in 200+ countries/regions, PhotonPay enables efficient, secure, and integrated global payments to drive business growth with infinite ambitions. Trusted by 200,000+ businesses worldwide to overcome banking and payment challenges, PhotonPay delivers simple, scalable, and customizable solutions – including accounts, card issuing, domestic/international payments, and embedded finance. With licenses and compliance coverage across strategic regions, PhotonPay’s unified infrastructure enables businesses to accelerate product development, enhance operational efficiency, and drive sustainable growth. Official website: https://www.photonpay.com/uk